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ABSTRACT 
Periodontitis was discovered in 15 out of the 40 pa-
tients affected by psoriasis, especially those affected 
by vulgaris psoriasis and arthropathic psoriasis. Fur-
thermore, smoking patients have an increased risk of 
developing periodontal’s disease. Duration and sever-
ity of disease did not influence the prevalence of oral 
lesions. 
Conclusion. Due to the strong match between pso-
riasis and oral lesions, dermatologists and oral health 
care providers have to cooperate efficiently being aware 
of the predisposition of psoriatic patients to different 
oral diseases. The goal of achieving and maintaining 
periodontal health leads to healthy and functional den-
tition in psoriatic patients and reduce the risk factors 
triggering psoriasis itself. 
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Aim. Tyrosine kinase inhibitors (TKIs) targeting tu-
mor angiogenesis and mammalian target of rapamycin 
inhibitors (mTOR) are indicated for the management 
of several cancer types, as for renal cell carcinoma 
(RCC). 
Oral ulcerations are reported as common adverse drug 
reactions of mTOR inhibitors and are currently classified 
as mTOR inhibitor associated stomatitis (mIAS). Inter-
estingly, these lesions appear as aphthous-like stoma-
titis rather than the mucositis seen with chemotherapy 
agent. 
Case report. A 49 years old male patient underwent 
to the left radical nephrectomy in May 2014 for clear 
RCC. From July to October 2014 he was treated with 
Pazopanib, a tyrosine kinase inhibitor. In December 
2014 the patient started the treatment with Zoledronic-
acid and Everolimus, an amino-bisphosphonates and an 
mTOR inhibitor, respectively. Everolimus administration 
was suspended on the 1st
 
of January 2015 and resumed 
on the 4th
 
of February. In February 2015, the patient re-
ferred to our department for acute pain of mouth floor 
and tongue; the onset of these symptoms was subse-
quent to mTOR therapy. This pain compromised his oral 
functions (chewing, swallowing, phonetic) and quality 
of life. Intraoral examination showed aphthous-like le-
sions on both borders of the tongue and on the right 
side of the mouth floor. 
Local antiseptic (0.2% chlorhexidine rinse, twice daily 
for 1 week), 0.050 g clobetasol propionate cream (twice 
a day for 4 week, and one times a day for the following 
4 weeks) and a wound-healing promoter (Mucosamin 
Spray®, twice a day for 2 weeks) were administered. 
Since the oncologist decided to not discontinue the tar-
get therapy, the patient continued local therapy until the 
end of the treatment with everolimus. 
After two weeks from the first visit, a complete heal-
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Aim. Psoriasis is a common multifactorial inflamma-
tory skin disease, affecting from 1% to 3% of the world 
population, with geographic and ethnic variations. It 
has a bimodal age distribution, with the earlier peak 
incidence between 15 and 30 years of age (Psoriasis 
Type I), and the later peak incidence between 50 and 
60 years of age (Psoriasis Type II). Psoriasis is clas-
sified clinically into several types: vulgaris, erythro-
dermic, guttate, onycodistrophy, pustular, inverse and 
psoriatic arthritis. Even though it is a common disor-
der, in International literature there are only few pub-
lications about its oral manifestations. Typical cutane-
ous lesions are flat polygonal red scaly-plaques, that 
evolve into hyperpigmented lesions. In the oral cavity, 
manifestations include small whitish papules that yield 
bleeding points when scraped and red/white plaques 
having the same trend of the skin lesions. Of inter-
est to the oral health care provider is the increased 
frequency of fissured and geographic tongue (FT and 
GT). Psoriasis and periodontitis have a common etio-
pathology; in fact, probing depth and periodontal at-
tachment level are significant higher in psoriatic pa-
tients. Patients affected by arthropathic psoriasis report 
Temporo-Mandibular Joint Disorders (TMJD). In addi-
tion, patients using methotrexate and cyclosporine as 
immunosuppressive therapy of psoriasis show higher 
risk to develop oral candidosis. The aim of this study 
is to investigate and compare the prevalence of oral 
mucosal lesions in a group of psoriatic patients and 
healthy subjects. 
Methods. 40 psoriatic patients, 24 males and 16 fe-
males, aged from 21 to 91 years old, followed in Der-
matology and Venereology Department of Policlinico 
Umberto I in Rome, were enrolled in this preliminary 
study. There were included 4 cases of psoriasis Type I 
and 36 of psoriasis Type II, counting 24 with diagno-
sis of vulgaris psoriasis, 9 with arthropathic psoriasis, 
2 with erythrodermic psoriasis, 4 with pustular pso-
riasis, 1 with guttate psoriasis. Clinical examination, 
Panoramic XR, Magnetic Nuclear Resonance (MNR) of 
Temporo Mandibular Joint (TMJ), parodontal evalua-
tion, oropharyngeal buffer and incisional biopsies by 
scalpel were done in order to value the patients. The 
control group was formed by 40 non-psoriatic patients 
of Odontostomatologic Clinic of Policlinico Umberto 
I in Rome. 
Results. According to International Literature data, 
we found out that there is a statistically significant 
difference between the number of patients with oral 
lesions in the psoriatic group as compared to the con-
trol group. The lesions positively related to psoriasis 
are FT and GT. 40% of psoriatic patients presents FT 
compared to 17% in the control group, while 7,5% 
of patients affected by psoriasis shows GT compared 
to 2,5% of the control group. TMJD was found in 
about half the patients with arthropathic psoriasis. 
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 ABSTRACT
hypertension and diabetes had lower cumulative dose 
related to the pathology onset. 
Conclusion. A group of MRONJ patients consecu-
tively treated in 11 years was analyzed. 
Data regarding diagnosis and treatment were exposed. 
Oncologic patient showed the worst clinical outcomes. Hy-
pertension, diabetes, and specific drug therapies that inter-
fere with the vascular asset of the patient are the most signi-
ficative risk factors involved, lowering the mean cumulative 
dose of the drug hastening the MRONJ onset. 
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Aim. Chronic Graft-Versus-Host Disease (cGVHD) is 
an immuno-mediated disorder occurring as a frequent 
complication of allogeneic Hematopoietic Stem Cell 
Transplantation (HSCT), and affecting multiple organ sys-
tem (skin, oral cavity, GI tract, lung, muscles and joints). 
Its prevalence is between 25-80 % in long-term survivors. 
The immune cells of the morrow bone donor mediates 
the immune attack to the recipient tissues. This immune 
attack probably causes an overstimulation of the apop-
totic processes, that play a role in the pathogenesis of 
this disease. Frequently, oral manifestations can be the 
first symptom of systemic GVHD (80%), presenting as 
atrophic-erosive and/or hyperkeratotic lesions that clini-
cally mimic autoimmune diseases such as Lichen Planus, 
Scleroderma, and Sjögren’s syndrome with oral inflamma-
tion and erythema, atrophy, fibrosis with narrow mouth, 
tongue depapillation, hyposalivation and pain. 
The aim of this study was to describe the development 
of oral carcinoma and its precursors in patients affected 
by GVHD and the importance of a periodical and careful 
oral follow-up of patients with oral GVHD to detect pre-
malignant or evident malignant lesions at an early stage. 
Methods. Ten consecutive patients undergoing first 
allogeneic HSCT from consanguineous were visited at 
the Complex Operative Unit of Odontostomatology, 
Policlinic of Bari and were included in this study. 
Clinical examination showed seventeen ulcerative, 
leukoplastic and/or erythroplastic lesions in different 
oral sites (tongue, cheek, retrocommissural side, lower 
lip). All these lesions underwent an incisional biopsy 
for histopathological assessment in order to assess the 
presence of dysplastic or neoplastic areas; specifically 
for neoplastic tissues, six prognostic factors were also 
evaluated: tumor thickness, invasion pattern (single cell, 
large front), vascular, neural, ducts of the salivary glands 
and muscle infiltration. 
Results. All the surgical wounds healed without 
complications. Histological examination highlighted: 
ing of the oral mucosa was observed and the patient 
complained no pain. 
Conclusion. This case report confirms the recent 
view that target therapy with everolimus may induce 
the onset of aphthous-like stomatitis as adverse drug 
reaction. Therefore, diagnostic algorithms for stomatitis 
should include a careful drug history, emphasizing the 
focus also on oral adverse effects the new target cancer 
therapies.
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Aim. Medication-related osteonecrosis of the jaw 
(MRONJ) is a well-recognized side-effect of medications 
prescribed in patients suffering from several forms of 
cancer, bone metastases from solid tumors, multiple my-
eloma and dismetabolic bone diseases. 
This study describes the 11 years experience of a Oral 
Surgery Unit in the management of patients affected by 
this avascular necrosis pathology of the maxillo-facial 
district, evaluating the relationship between risk factors 
and onset and progression of this maxillary pathology. 
Methods. During a period ranging from 2005 to 2015 
a group of 93 patients affected by MRONJ was consecu-
tively observed and treated by the Oral Surgery Unit 
of the University of Messina -School of Dentistry.The 
patients (23 males, 70 females) aged between 46 and 
89 years. 
MRONJ diagnosis and staging was assessed according 
to the SIPMO - SICMF criteria, adopting a work-flow 
including CT examinations. 
According to the MRONJ stage, antimicrobial therapy 
(systemic antibiotics and topical antiseptics) surgical 
treatment (sequestrectomy, alveolar resection) and/or 
palliative treatments were adopted to manage the pa-
tients. 
Different parameters were evaluated to analyze 
MRONJ onset and progression: demographic data; local 
risk factors (tooth extraction, oral infections, decubitus 
ulcers by dental prosthesis, etc.); systemic risk factors 
(diabetes, hypertension, etc.); cumulative dose of each 
medication taken on, contemporary and/or consecutive 
assumption of different at risk drugs. 
Statistical analysis was conducted using multiple re-
gression, ANOVA and Spearman correlation. 
A scoring system to evaluate the severeness of the 
MRONJ was used considering the following phenom-
ena (indicating with 0 the absence of event and with 1 
its presence): pain, bone exposure, purulent discharge, 
extra-oral fistula, displaced mandibular stumps, nasal 
leakage of fluids. 
Results. The statistical analysis showed how the 
MRONJ is far more severe in the oncologic patients 
treated with zoledronic acid, with a strong correlation 
between the cumulative dose and the MRONJ score. The 
data demonstrate how the main oral triggers are tooth 
extraction, periodontal disease and decubitus ulcers by 
dental prosthesis. On the other hand, drug therapies in-
cluding steroids and antiangiogenic factors, as long as 
